230,975 Shares in Astrana Health, Inc. (NASDAQ:ASTH) Purchased by Principal Financial Group Inc.

Principal Financial Group Inc. acquired a new stake in shares of Astrana Health, Inc. (NASDAQ:ASTH) in the third quarter, Holdings Channel reports. The fund acquired 230,975 shares of the company’s stock, valued at approximately $13,383,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. GAMMA Investing LLC acquired a new stake in shares of Astrana Health in the third quarter worth $34,000. Nisa Investment Advisors LLC acquired a new position in Astrana Health during the third quarter valued at $35,000. Central Pacific Bank Trust Division purchased a new stake in Astrana Health in the 3rd quarter worth about $160,000. Everence Capital Management Inc. acquired a new stake in Astrana Health during the 3rd quarter worth about $272,000. Finally, Granite Bay Wealth Management LLC purchased a new position in Astrana Health during the 3rd quarter valued at about $290,000. 52.77% of the stock is currently owned by institutional investors and hedge funds.

Astrana Health Stock Performance

ASTH stock opened at $40.81 on Friday. The firm has a 50 day moving average of $55.04 and a two-hundred day moving average of $47.74. Astrana Health, Inc. has a 12 month low of $32.04 and a 12 month high of $63.20. The company has a market capitalization of $2.30 billion, a price-to-earnings ratio of 31.39, a P/E/G ratio of 1.96 and a beta of 1.24. The company has a quick ratio of 1.84, a current ratio of 1.91 and a debt-to-equity ratio of 0.60.

Astrana Health (NASDAQ:ASTH) last posted its earnings results on Thursday, November 7th. The company reported $0.33 EPS for the quarter, hitting the consensus estimate of $0.33. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. The firm had revenue of $478.71 million for the quarter, compared to the consensus estimate of $462.01 million. During the same period in the prior year, the business posted $0.47 earnings per share. As a group, equities analysts anticipate that Astrana Health, Inc. will post 1.16 EPS for the current fiscal year.

Analysts Set New Price Targets

ASTH has been the subject of a number of research analyst reports. Robert W. Baird increased their price target on shares of Astrana Health from $67.00 to $86.00 and gave the stock an “outperform” rating in a research report on Wednesday. Truist Financial upped their price objective on shares of Astrana Health from $50.00 to $59.00 and gave the company a “buy” rating in a research note on Friday, August 9th. TD Cowen started coverage on shares of Astrana Health in a research note on Monday, October 14th. They set a “buy” rating and a $66.00 target price for the company. BTIG Research boosted their price target on shares of Astrana Health from $60.00 to $70.00 and gave the company a “buy” rating in a report on Thursday, October 3rd. Finally, KeyCorp assumed coverage on Astrana Health in a report on Friday, October 11th. They set a “sector weight” rating for the company. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $65.17.

Astrana Health Company Profile

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.